Back to top

Image: Bigstock

Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

Read MoreHide Full Article

Key Takeaways

  • Cencora expects specialty distribution revenues of approximately $100 billion in fiscal 2027, fueling growth.
  • COR's MSO acquisitions expand its oncology and retina networks, supporting specialty operating income growth.
  • COR faces fiscal 2027 headwinds from customer volume shifts, price cuts and divestitures, weighing on growth.

Cencora’s (COR - Free Report) fourth-quarter results highlighted the company's strategic shift toward specialty pharmaceuticals, supported by acquisitions, expanding provider relationships and investments in specialty logistics. Its pharmaceutical distribution business continues to provide scale, while the new reporting structure offers greater visibility into the growth potential of specialty operations. However, customer volume shifts, pricing-related revenue pressure and portfolio restructuring could temper reported growth in fiscal 2027.

This Zacks Rank #3 (Hold) company’s shares have gained 3.7% in the year-to-date period compared with the industry’s 8.9% growth. However, the S&P 500 Index has gained 7.2% in the same time frame.

Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $68.11 billion.

Zacks Investment Research
Image Source: Zacks Investment Research

COR’s bottom line is anticipated to improve 9.9% over the next five years. Its earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 0.98%.

Let’s delve deeper.

Positive Factors Driving COR’s Prospects

Expanding Specialty Pharmaceutical Platform: Cencora's increasing focus on specialty pharmaceuticals positions it to benefit from a market growing faster than the broader pharmaceutical industry. Management noted that specialty market growth has been approximately twice that of the overall market over the past five years, with biologics now accounting for more than half of U.S. pharmaceutical spending.

The company expects specialty distribution revenues to reach approximately $100 billion in fiscal 2027. Its capabilities across distribution, clinical trial logistics, commercialization and provider services create opportunities to participate across the pharmaceutical product lifecycle. This integrated platform could support sustained growth and strengthen Cencora's competitive positioning.

MSO Acquisitions Pave Way to High-Growth Markets: Cencora's investments in management services organizations (MSOs) are expanding its reach across specialty physician practices. The OneOncology acquisition, completed in February 2026, has strengthened its oncology presence, while the planned acquisitions of EyeSouth's retina business and a majority interest in American Oncology Network should further broaden its provider network. These platforms also create opportunities to support pharmaceutical companies through clinical trials, commercialization and patient access.

MSOs accounted for approximately 10% of enterprise operating income in fiscal 2026. These acquisitions are expected to increase the segment’s contribution and accelerate operating income growth. Continued physician acquisition and tuck-in transactions could support the specialty segment's targeted mid-teens long-term operating income growth.

Global Presence in Specialty Logistics: Cencora's global specialty logistics and third-party logistics (3PL) businesses are benefiting from the increasing complexity of pharmaceutical pipelines and the need to transport innovative therapies across markets. In the fourth quarter of fiscal 2026, the international segment's operating income increased 16% on a reported basis and 19% at constant currency, supported by double-digit growth in global specialty logistics and 3PL.

Management highlighted investments in specialized logistics capabilities across more than 50 countries, positioning the company to support manufacturers as they launch increasingly complex therapies. Strong program win rates in Canada also contributed to international performance. These capabilities could provide an additional source of growth beyond traditional pharmaceutical distribution.

Challenges for COR Stock

Customer Volume Shifts and Currency Pressure: Cencora's Pharmaceutical Distribution and Services business faces a relatively subdued growth outlook for fiscal 2027. Management expects segment operating income growth of just 2-4%, below its long-term mid-single-digit target. This outlook incorporates the wraparound impact of a previously disclosed customer volume shift and an approximately 1-percentage-point foreign-exchange headwind.

The impact is significant because pharmaceutical distribution remains the company's largest operating platform. Management expects underlying performance to stay in line with its long-term targets once these effects subside. In the near term, these headwinds could limit the segment’s earnings growth and leave it contributing less than specialty operations.

Manufacturer Price Reductions Offset GLP-1 and Specialty Growth: Cencora's U.S. Healthcare Solutions business continues to face revenue pressure from manufacturer list-price reductions, which can offset growth in higher-demand pharmaceutical categories. In the fourth quarter, GLP-1 sales increased $2.8 billion year over year, but manufacturer price reductions rendered an equivalent $2.8 billion headwind to revenue growth.

A decline in sales to a major mail-order customer added to the pressure. While specialty sales to health systems and physician practices remained strong, these offsetting factors illustrate the challenge of translating higher pharmaceutical volumes into reported revenue growth. Continued pricing adjustments could therefore limit top-line expansion even if demand for innovative therapies remains healthy.

Portfolio Restructuring and Divestitures: Cencora's portfolio simplification strategy is expected to create near-term pressure on reported fiscal 2027 growth. Management expects the Profarma divestiture and the anticipated mid-year MWI-Covetrus merger to create a combined headwind of approximately 150 basis points to consolidated revenue growth.

The businesses classified under Other are also expected to reduce operating income growth by approximately five percentage points, largely because of the assumed MWI-Covetrus transaction. Consequently, headline operating income growth is projected at 4-6% compared with 8.5-11%, excluding Other businesses. Although the restructuring sharpens strategic focus, it complicates comparisons and could temper reported growth.

Estimate Trend

COR has been witnessing a declining revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for earnings has moved south 6 cents to $19.71 per share. Although the EPS estimate declined, it reflects 9.7% year-over-year growth.

The consensus mark for first-quarter fiscal 2027 revenues is pegged at $90.61 billion, indicating a 5.5% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $4.53, implying year-over-year growth of 11%.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .

Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with the average surprise being 138.6%.

Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.

Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 15.1%.

West Pharmaceutical, currently carrying a Zacks Rank of 2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.

WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 18.6%.

Published in